Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Cohen

Showing results (921-930 of 1,023) with videos related to

Pageof 103
Sort By:
Journal of Translational Medicine|December 28, 2019
SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neckSara I Pai, Ezra E W Cohen, Derrick Lin, et al.
American Journal of Physiology. Cell Physiology|October 22, 2002
Caveolin-1 null mice develop cardiac hypertrophy with hyperactivation of p42/44 MAP kinase in cardiac fibroblastsAlex W Cohen, David S Park, Scott E Woodman, et al.
Chest|July 23, 2016
Bronchial Reactivity and Lung Function After World Trade Center ExposureThomas K Aldrich, Jessica Weakley, Sean Dhar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 2009
Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]J Simon W Stewart, Ezra E W Cohen, Lisa Licitra, et al.
Journal of the National Cancer Institute|May 15, 2020
Quality of Life With Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040Kevin J Harrington, Denis Soulières, Christophe Le Tourneau, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2021
Intralesional SD-101 in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Head and Neck Squamous Cell Carcinoma: Results from a Multicenter, Phase II TrialEzra E W Cohen, Lisle Nabell, Deborah J Wong, et al.
Journal of Clinical Epidemiology|October 1, 2020
PCORnet® 2020: current state, accomplishments, and future directionsChristopher B Forrest, Kathleen M McTigue, Adrian F Hernandez, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 25, 2015
Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumorsS J Wong, T Karrison, D N Hayes, et al.
Frontiers in Immunology|September 8, 2017
RTS,S/AS01E Malaria Vaccine Induces Memory and Polyfunctional T Cell Responses in a Pediatric African Phase III TrialGemma Moncunill, Stephen C De Rosa, Aintzane Ayestaran, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 3, 2025
Xevinapant or Placebo Plus Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (TrilynX): A Randomized, Phase III StudyJean Bourhis, Lisa F Licitra, Barbara Burtness, et al.
Pageof 103

Showing results (921-930 of 1,023) with videos related to

Sort By:
Pageof 103
Journal of Translational Medicine|December 28, 2019
SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neckSara I Pai, Ezra E W Cohen, Derrick Lin, et al.
American Journal of Physiology. Cell Physiology|October 22, 2002
Caveolin-1 null mice develop cardiac hypertrophy with hyperactivation of p42/44 MAP kinase in cardiac fibroblastsAlex W Cohen, David S Park, Scott E Woodman, et al.
Chest|July 23, 2016
Bronchial Reactivity and Lung Function After World Trade Center ExposureThomas K Aldrich, Jessica Weakley, Sean Dhar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 2009
Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]J Simon W Stewart, Ezra E W Cohen, Lisa Licitra, et al.
Journal of the National Cancer Institute|May 15, 2020
Quality of Life With Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040Kevin J Harrington, Denis Soulières, Christophe Le Tourneau, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2021
Intralesional SD-101 in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Head and Neck Squamous Cell Carcinoma: Results from a Multicenter, Phase II TrialEzra E W Cohen, Lisle Nabell, Deborah J Wong, et al.
Journal of Clinical Epidemiology|October 1, 2020
PCORnet® 2020: current state, accomplishments, and future directionsChristopher B Forrest, Kathleen M McTigue, Adrian F Hernandez, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 25, 2015
Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumorsS J Wong, T Karrison, D N Hayes, et al.
Frontiers in Immunology|September 8, 2017
RTS,S/AS01E Malaria Vaccine Induces Memory and Polyfunctional T Cell Responses in a Pediatric African Phase III TrialGemma Moncunill, Stephen C De Rosa, Aintzane Ayestaran, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 3, 2025
Xevinapant or Placebo Plus Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (TrilynX): A Randomized, Phase III StudyJean Bourhis, Lisa F Licitra, Barbara Burtness, et al.
Pageof 103